Search Results

There are 4728 results for: content related to: Cardiovascular risk of selective cyclooxygenase-2 inhibitors and other non-aspirin non-steroidal anti-inflammatory medications

  1. Enhancement of dissolution rate of rofecoxib using solid dispersions with urea

    Drug Development Research

    Volume 63, Issue 4, December 2004, Pages: 181–189, Chengsheng Liu, Kashappa Goud H. Desai, Chenguang Liu and Hyun J. Park

    Version of Record online : 28 MAR 2005, DOI: 10.1002/ddr.10412

  2. The effect of rofecoxib on the pharmacodynamics and pharmacokinetics of warfarin

    Clinical Pharmacology & Therapeutics

    Volume 68, Issue 6, December 2000, Pages: 626–636, Jules I. Schwartz, Kathleen J. Bugianesi, David L. Ebel, Marina De Smet, Rita Haesen, Patrick J. Larson, Amy Ko, Rene Verbesselt, Thomas L. Hunt, Robert Lins, Simone Lens, Arturo G. Porras, John Dieck, Bart Keymeulen and Barry J. Gertz

    Version of Record online : 12 DEC 2000, DOI: 10.1067/mcp.2000.112244

  3. NSAIDs – COX-2 Inhibitors – Risks and Benefits

    Pharmacovigilance, Second Edition

    K. Arnold Chan, S. Christopher Jones, Pages: 583–602, 2007

    Published Online : 7 FEB 2007, DOI: 10.1002/9780470059210.ch47

  4. Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study

    Pharmacoepidemiology and Drug Safety

    Volume 16, Issue 5, May 2007, Pages: 493–503, Elham Rahme, Douglas J. Watson, Sheldon X. Kong, Youssef Toubouti and Jacques LeLorier

    Version of Record online : 6 NOV 2006, DOI: 10.1002/pds.1339

  5. You have free access to this content
    Arthritis & Rheumatism, 2001 Annual Scientific Meeting Abstracts, November 10–15, 2001, San Francisco, CA

    Arthritis & Rheumatism

    Volume 44, Issue S9, September 2001, Pages: 277–390,

    Version of Record online : 22 FEB 2002, DOI: 10.1002/1529-0131(200109)44:9+<::AID-ART427>3.0.CO;2-4

  6. Cardiovascular Risks of Cyclooxygenase Inhibition

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 26, Issue 7, July 2006, Pages: 919–938, Dr. Zachary A. Stacy, Dr. Paul P. Dobesh and Dr. Toby C. Trujillo

    Version of Record online : 6 JAN 2012, DOI: 10.1592/phco.26.7.919

  7. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model

    Clinical Pharmacology & Therapeutics

    Volume 65, Issue 3, March 1999, Pages: 336–347, Elliot W. Ehrich, Aimee Dallob, Inge De Lepeleire, Anne Van Hecken, Denis Riendeau, Weiying Yuan, Arturo Porras, Johanna Wittreich, James R. Seibold, Paul De Schepper, Donald R. Mehlisch and Barry J. Gertz

    Version of Record online : 10 MAR 1999, DOI: 10.1016/S0009-9236(99)70113-X

  8. Lack of Pharmacokinetic Interaction between Rofecoxib and Methotrexate in Rheumatoid Arthritis Patients

    The Journal of Clinical Pharmacology

    Volume 41, Issue 10, October 2001, Pages: 1120–1130, Dr. Jules I. Schwartz, Dr. Nancy G. B. Agrawal, Dr. Peggy H. Wong, Dr. Kenneth A. Bachmann, Dr. Arturo G. Porras, Ms. Jutta L. Miller, Mr. David L. Ebel, Dr. Marshall R. Sack, Dr. Gregory B. Holmes, Dr. Jan S. Redfern and Dr. Barry J. Gertz

    Version of Record online : 8 MAR 2013, DOI: 10.1177/00912700122012616

  9. NSAID switching and short-term gastrointestinal outcome rates after the withdrawal of rofecoxib

    Pharmacoepidemiology and Drug Safety

    Volume 18, Issue 12, December 2009, Pages: 1134–1142, Sebastian Schneeweiss, Robert J. Glynn, Jerry Avorn, Muhammad Mamdani, Helen Mogun and Daniel H. Solomon

    Version of Record online : 20 OCT 2009, DOI: 10.1002/pds.1826

  10. High frequency of use of rofecoxib at greater than recommended doses: cause for concern

    Pharmacoepidemiology and Drug Safety

    Volume 13, Issue 6, June 2004, Pages: 339–343, Marie R. Griffin, C. Michael Stein, David J. Graham, James R. Daugherty, Patrick G. Arbogast and Wayne A. Ray

    Version of Record online : 15 JUL 2003, DOI: 10.1002/pds.879

  11. A New Cyclooxygenase-2 Inhibitor, Rofecoxib (VIOXX®), Did Not Alter the Antiplatelet Effects of Low-Dose Aspirin in Healthy Volunteers

    The Journal of Clinical Pharmacology

    Volume 40, Issue 12, December 2000, Pages: 1509–1515, Dr. Howard E. Greenberg, Dr. Keith Gottesdiener, Ms. Martha Huntington, Ms. Peggy Wong, Ms. Pat Larson, Ms. Lynn Wildonger, Ms. Lisa Gillen, Ms. Ellen Dorval and Dr. Scott A. Waldman

    Version of Record online : 19 MAR 2013, DOI: 10.1177/009127000004001224

  12. An Evaluation of the Dose-Dependent Inhibition of CYP1A2 by Rofecoxib Using Theophylline as a CYP1A2 Probe

    The Journal of Clinical Pharmacology

    Volume 43, Issue 10, October 2003, Pages: 1082–1090, Dr. Kenneth Bachmann, Dr. Donald White, Dr. Luis Jauregui, Dr. Jules I. Schwartz, Dr. Nancy G. B. Agrawal, Mr. Ralph Mazenko, Mr. Patrick J. Larson and Dr. Arturo G. Porras

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270003257454

  13. Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans

    Clinical Pharmacology & Therapeutics

    Volume 65, Issue 6, June 1999, Pages: 653–660, Jules I. Schwartz, Chi-Chung Chan, Saurabh Mukhopadhyay, Kathleen J. McBride, Terry M. Jones, Sherilyn Adcock, Carl Moritz, Jerris Hedges, Kenneth Grasing, David Dobratz, Robert A. Cohen, Michael H. Davidson, Kenneth A. Bachmann and Barry J. Gertz

    Version of Record online : 17 JUN 1999, DOI: 10.1016/S0009-9236(99)90087-5

  14. You have free access to this content
    Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: Results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip

    Arthritis & Rheumatism

    Volume 43, Issue 5, May 2000, Pages: 978–987, Grant W. Cannon, Jacques R. Caldwell, Peter Holt, Barry McLean, Beth Seidenberg, James Bolognese, Elliot Ehrich, Suarabh Mukhopadhyay and Brian Daniels

    Version of Record online : 2 APR 2001, DOI: 10.1002/1529-0131(200005)43:5<978::AID-ANR4>3.0.CO;2-0

  15. The trade-off between cardiovascular and gastrointestinal effects of rofecoxib

    Pharmacoepidemiology and Drug Safety

    Volume 14, Issue 7, July 2005, Pages: 437–441, Stefan R. Florentinus, Eibert R. Heerdink, Antonius de Boer, Liset van Dijk and Hubert G. M. Leufkens

    Version of Record online : 2 JUN 2005, DOI: 10.1002/pds.1123

  16. Effect of Rofecoxib on Prednisolone and Prednisone Pharmacokinetics in Healthy Subjects

    The Journal of Clinical Pharmacology

    Volume 43, Issue 2, February 2003, Pages: 187–192, Jules I. Schwartz, Saurabh Mukhopadhyay, Arturo G. Porras, Kala-Jyoti Viswanathan-Aiyer, Sherilyn Adcock, David L. Ebel and Barry J. Gertz

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270002239828

  17. Comparative Inhibitory Activity of Rofecoxib, Meloxicam, Diclofenac, Ibuprofen, and Naproxen on COX-2 versus COX-1 in Healthy Volunteers

    The Journal of Clinical Pharmacology

    Volume 40, Issue 10, October 2000, Pages: 1109–1120, Dr. Anne van Hecken, Dr. Jules I. Schwartz, Dr. Marleen Depré, Dr. Inge de Lepeleire, Ms. Aimee Dallob, Dr. Wesley Tanaka, Ms. Kathleen Wynants, Dr. Agnes Buntinx, Dr. Jef Arnout, Ms. Peggy H. Wong, Mr. David L. Ebel, Dr. Barry J. Gertz and Dr. Paul J. de Schepper

    Version of Record online : 8 MAR 2013, DOI: 10.1177/009127000004001005

  18. Abstracts of the 21st International Conference on Pharmacepidemiology & Therapeutic Risk Management

    Pharmacoepidemiology and Drug Safety

    Volume 14, Issue S2, September 2005, Pages: S1–S218,

    Version of Record online : 15 AUG 2005, DOI: 10.1002/pds.1136

  19. You have free access to this content
    Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial

    Arthritis & Rheumatism

    Volume 43, Issue 2, February 2000, Pages: 370–377, Christopher Hawkey, Loren Laine, Thomas Simon, Andre Beaulieu, Jose Maldonado-Cocco, Eduardo Acevedo, Aditi Shahane, Hui Quan, James Bolognese and Eric Mortensen

    Version of Record online : 2 APR 2001, DOI: 10.1002/1529-0131(200002)43:2<370::AID-ANR17>3.0.CO;2-D

  20. Effect of inflammation on kidney function and pharmacokinetics of COX-2 selective nonsteroidal anti-inflammatory drugs rofecoxib and meloxicam

    Journal of Applied Toxicology

    Volume 28, Issue 7, October 2008, Pages: 829–838, Sam Harirforoosh and Fakhreddin Jamali

    Version of Record online : 14 MAR 2008, DOI: 10.1002/jat.1342